Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235479 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study in Adult Subjects With Acute Migraines
A Phase 3 study of Migraine With or Without Aura, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,485
- Enrollment target
- 20
- Study locations
NCT03235479: Completed Phase 3 study of Migraine With or Without Aura, sponsored by Pfizer.
NCT03235479 is a Phase 3 study of Migraine With or Without Aura that has completed, run by Pfizer. The registered enrollment target is 1,485 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03235479, a Phase 3 study of Migraine With or Without Aura, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,485 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
Primary Outcome
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic diary (eDiary). Pain freedom was defined as pain level of none.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimegepant
Study Locations (20)
Florida
- Qps Mra, Llc - Hollywood
- Multi-Specialty Research Associates, Inc - Lake City
- Qps Mra, Llc - Miami
- Advanced Pharma CR, LLC - Miami
- Compass Research, LLC - Orlando
- Ormond Medical Arts Pharmaceutical Research - Ormond Beach
California
- Pharmacology Research Institute - Encino
- Optimus Medical Group - San Francisco
- California Medical Clinic for Headache - Santa Monica
- Diablo Clinical Research, Inc - Walnut Creek
Arizona
- Neurological Physicians of Arizona/Radiant Research Inc - Gilbert
- Clinical Research Consortium Arizona - Tempe
- Radiant Research, Inc. - Tucson
Massachusetts
- Boston Clinical Trials, Inc - Boston
- Milford Emergency Associates, Inc. - Marlborough
Alabama
- Central Research Associates, Inc - Birmingham
Arkansas
- Woodland International Research Group, LLC - Little Rock
Georgia
- Meridian Clinical Research - Savannah
Louisiana
- New Orleans Center for Clinical Research - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,485 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2018-01-26 |
| Phase | Phase 3 |
What the finished NCT03235479 record still lists
NCT03235479 is an interventional study that assigns participants to a tested intervention. Its 1,485 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% higher).
The record links to 1 condition, with Migraine With or Without Aura appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03235479 names 20 study sites across 9 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03235479 about?
NCT03235479 is a clinical study titled "Safety and Efficacy Study in Adult Subjects With Acute Migraines". The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
What is the current status of trial NCT03235479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,485 participants. The study started on 2017-07-18. Estimated completion is 2018-01-26.
What conditions does trial NCT03235479 study?
This clinical trial studies the following conditions: Migraine With or Without Aura.
What interventions are being tested in trial NCT03235479?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03235479?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03235479 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine With or Without Aura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03235479's enrollment target sits among peer trials
1,485 163rd of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI